Article

Intracorneal inlay approved in Korea

The Korean Food and Drug Administration (KFDA) has approved an intracorneal inlay (Kamra, AcuFocus) for presbyopia.

Irvine, CA-The Korean Food and Drug Administration (KFDA) has approved an intracorneal inlay (Kamra, AcuFocus) for presbyopia.

“We are extremely thrilled to be able to offer this advanced vision correction technology in Korea,” said Ed Peterson, AcuFocus president and chief executive officer. “The approval from the KFDA is a testament to the excellent global results achieved with the device.”

The device offers an alternative to reading glasses, contact lenses, and monovision LASIK. It is designed to create a small-aperture effect, allowing the eye to see near and intermediate objects more clearly while maintaining distance vision. By applying the “depth-of-focus” principle commonly used in photography, the inlay controls light transmission, allowing only central rays to reach the retina through a fixed, 1.6-mm aperture.

“We are confident that the Korean market will be eager to take advantage of this advanced treatment option, and we are excited to facilitate that process,” said In-Bum Choi, chief executive officer of Woo Jeon Medical, which distributes the inlay in Korea.

The device is considered an investigational device in the United States and has received CE mark for use in the European Union. To date, it has been implanted in more than 11,000 patients and is available in 35 countries in Europe, Asia, the Middle East, and South America.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.